Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

NCT06396416 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether it is feasible to recruit people with obesity and chronic kidney disease who are planning to have a kidney transplant.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind study

Participants 60 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-09 · est. completion 2026-02

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT06396416 ↗

Description as written by the study sponsor.

OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.

Treatments tested

Semaglutide also known as GLP-1RA, Ozempic, Wegovy Drug

Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
Virtual Weight Management Coaching Behavioral

Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.

Main thing measured	Feasibility of Recruitment
Sponsor	Western University, Canada
Conditions studied	Obesity, Chronic Kidney Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06396416 ↗